Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX:…

The wholesale purchase acquisition will preserve Fiery as an independent DFE provider and strengthen its industry leadership. FREMONT, Calif., Sept. 18, 2024 /PRNewswire/ — Fiery, LLC (“Fiery”), the print industry’s leading innovator of digital front ends (DFEs) and workflow software,…

Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development expected to enable commercial-scale production of the API in 2025 SUNNYVALE, Calif., Sept. 18, 2024 /PRNewswire/ – Willow Biosciences Inc….

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.